Status:
UNKNOWN
The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
VitaK
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of cardiovascular events. The development of arterial calcification results from imbalance between calcificat...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Baseline Coronary Computed Tomographic Angiography (CCTA) of sufficient quality
- Baseline Agatston calciumscore 100 - 400
Exclusion
- Baseline-scan of insufficient quality
- Heart rate greater than 70 beats per minute during first scan.(despite adequate treatment with metoprolol)
- Chronic or paroxysmal Atrial Fibrillation
- Presence or scheduled coronary revascularization procedure
- History of myocardial infarction or stroke.
- Presence of Diabetes Mellitus.
- Known kidney disease or a Glomerular Filtration Rate (GFR)MDRD \< 60 ml/min/1.73m2
- Malignant disease (exception: treated basal-cell or squamous cell carcinoma).
- Use of Vitamin K antagonists.
- A life-expectancy \< 2 years
- Pregnancy or wish to become pregnant in the near future.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT01002157
Start Date
October 1 2011
End Date
October 1 2019
Last Update
September 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Netherlands, 6202 AZ